Radiofrequency Ablation Mapping with Circumferential Catheter for Paroxys- mal Atrial Fibrillation Originating From the Pulmonary Veins

Objectives To assessed the feasibility and effectiveness of electrophysiological mapping of pulmonary veins with a circumferential 10 - electrode catheter and radiofrequency catheter ablation therapy for patients with paroxysmal atrial fibrillation. Background Standard mapping and ablation of focal sources of atrial fibrillation are associated with very long procedure times and low efficacy. Mapping and ablation pulmonary veins guide with a circular catheter could overcome these limitations. Methods 16 patients [male 11, female 5, mean age (51 ±14. 5) years] with paroxysmal atrial fibrillation refractory to antiarrhythmic drugs were included in this group. A circumferential 10 - electrode catheter was used to pulmonary vein mapping during sinus rhythm or CSd pacing to determine the origin of atrial premature contractions. When the ablative target pulmonary vein was found, the pulmonary vein potentials' distribution and activation were assessment pulmonary veins' ostial ablation was performed at the segments showing earliest activation of pulmonary vein potentials. The end point was designed: 1) elimination of pulmonary vein potential; 2) pulmonary vein potential dissociation from atrial waves; 3) atrial ectopic beats disappear. Results A total of 36 pulmonary veins were ablated, including 16 left superior, 12 right superior, 7 left inferior and 1 right inferior. 1 pulmonary vein in 2 patients was ablated, 2 pulmonary veins in 8 patients were ablated, 3 pulmonary veins were ablated in 5 patients and 4 pulmonary veins were ablated in 1 pa- tient. Procedure duration and fluoroscopy time respectively were 186. 7±63. 8 min and 51. 5±15. 0 min. During the follow-up 1-12 months, 11 patients (68. 7 % ) were free of AF without any antiarrhythmic drugs, 2 of them were reablation, effective in 3/16 (18. 7 % ) and unsuccessful in 2/16 (12. 6 % ) . 2 cases recurred with atrial premature, 1 was treated with amiodarone and the other was repeat electrophysiologi-cal mapping and ablation, 5 cases with paroxysmal a-trial fibrillation recurred, 3 of them were treated with amiodarone (2 cases) or sotalol (1 case) , one was implantled with DDDR pacemaker (having programmer of anti - atrial fibrillation), one was repeat ablation. PV's diameter in 2 of them reduced more than 50 % , but they were asymptomatic during the follow - up period. 1 case had pneumothorax complication and disappeared after 7 days. Conclusions This study suggests that careful mapping and elimination of these ectopic foci under the guide of circular catheter may have higher success rate and splendid future.

Segmental radiofrequency ablation of pulmonary vein ostia for patients with refractory paroxysmal atrial fibrillation using multi-slice spiral computed tomography guidance

Objective： To evaluate the safety and clinical efficacy of segmental radiofrequency ablation of pulmonary vein （PV） ostia for patients with refractory paroxysmal atrial fibrillation （AF） under multi-slice spiral computed tomography （MSCT） guidance before the procedure. Methods： A series of 58 consecutive patients with refractory paroxysmal AF were enrolled to undergo segmental radiofrequency ablation ofPV ostia. The 36 male and 22 female patients with mean age of （57.4±9.5） （32-79） years and no obvious organic heart disease. Before ablation, patients received MSCT to generate 3-dimentional image of the left atrium （LA） and proximal PVs. Patients then underwent segmental radiofrequency ablation ofPV ostia using PV circular mapping catheter manipulated several times to ensure complete isolation between PVs and LA. Results： No complications occurred during the procedure. One patient developed delayed cardiac tamponade, which was drained percutaneously. The mean follow-up time was （17.1±9.3） months. Forty-one patients （95%） experienced improved quality of life one month after the procedure. Thirty-six patients （83%） showed stable sinus rhythm, while 10 patients （23%） required additional anti-arrhythmic drugs. AF returned≥1 time in 6 （14%） patients who underwent anti-arrhythmic drug therapy, but the number of episodes was less than that before the procedure. However, one patient experienced recurrent episodes of atrial flutter. Conclusion： It is safe and effective to perform segmental radiofrequency ablation of PV ostia for patients with refractory paroxysmal AF using MSCT guidance mappening.

Hemoptysis secondary to pulmonary vein stenosis after radiofrequency ablation for atrial fibrillation: A case report and literature review

Objectives: Pulmonary vein stenosis(PVS) is a known complication after radiofrequency ablation of atrial fibrillation(RAAF) and is often misdiagnosed owing to lack of awareness regarding PVS among noncardiologists.Misdiagnosis results in unnecessary treatment;therefore, greater understanding of PVS can improve the management of these patients.Methods: We report the case of a 38-year-old man with a history of RAAF who presented with massive hemoptysis.His symptoms persisted despite undergoing transcatheter bronchial artery embolization on two occasions.Results: Pulmonary computed tomography angiography revealed a completely occluded left superior pulmonary vein. Considering the patient’s history of RAAF, we diagnosed him with RAAF-induced PVS and performed left superior lobectomy after which hemoptysis did not recur.Conclusions: Unexplained massive hemoptysis should alert clinicians regarding the possibility of RAAF-induced PVS. Balloon angioplasty and stent placement are used to treat PVS;however, their efficacy is controversial considering the high recurrence rates associated with these interventions.

Mechanisms and clinical significance of early recurrences of atrial arrhythmias after catheter ablation for atrial fibrillation

Early recurrence of atrial arrhythmias(ERAA) after ablation is common and strongly predicts late recurrences and ablation failure. However, since arrhythmia may eventually resolve in up to half of patients with ERAA, guidelines do not recommend immediate reintervention for ERAA episodes occurring during a 3-mo postablation blanking period. Certain clinical demographic, electrophysiologic, procedural, and ERAA-related characteristics may predict a higher likelihood of longterm ablation failure. In this review, we aim to discuss potential mechanisms of ERAA, and to summarize the clinical significance, prognostic implications, and treatment options for ERAA.

Catheter ablation of atrial fibrillation: Radiofrequency catheter ablation for redo procedures after cryoablation

AIM: To evaluate the effectiveness of two different strategies using radiofrequency catheter ablation for redo procedures after cryoablation of atrial fibrillation.METHODS: Thirty patients(paroxysmal atrial fibrillation: 22 patients,persistent atrial fibrillation: 8 patients) had to undergo a redo procedure after initially successful circumferential pulmonary vein(PV) isolation with the cryoballoon technique(Arctic Front Balloon,CryoCath Technologies/Medtronic).The redo ablation procedures were performed using a segmental approach or a circumferential ablation strategy(CARTO;Biosense Webster) depending on the intra-procedural findings.After discharge,patients were scheduled for repeated visits at the arrhythmia clinic.A 7-day Holter monitoring was performed at 3,12 and 24 mo after the ablation procedure.RESULTS: During the redo procedure,a mean number of 2.9 re-conducting pulmonary veins(SD ± 1.0 PVs) were detected(using a circular mapping catheter).In 20 patients,a segmental approach was sufficient to eliminate the residual pulmonary vein conduction because there were only a few recovered pulmonary vein fibres.In the remaining 10 patients,a circumferential ablation strategy was used because of a complete recovery of the PV-LA conduction.All recovered pulmonary veins could be isolated successfully again.At 2-year follow-up,73.3% of all patients were free from an arrhythmia recurrence(22/30).There were no major complications.CONCLUSION: In patients with an initial circumferential pulmonary vein isolation using the cryoballoon technique,a repeat ablation procedure can be performed safely and effectively using radiofrequency catheter ablation.

A three-pulmonary vein isolation approach to treat paroxysmal atrial fibrillation

Objective To investigate the safety and efficacy of a 3-pulmonary vein (PV) isolation approach in treating paroxysmal atrial fibrillation (AF). Methods Radiofrequency catheter ablation was used to eliminate PV potential in 11 patterns with frequent paroxysmal AF refractory to anti-arrhythmic agents. During sinus rhythm, PV potential was mapped in the left and right superior PVs and left inferior PV. The procedural success was defined as the elimination of PV potential in the 3 PVs. Restults PV potential was identified and abolished in a total of 24 PVs, mostly in the left and right superior PV. There was no pulmonary stenosis or other complications during or after the procedures. AF recurred in one patient after an average of 12 ± 3 month follow-up. Conclusions PV potemials were present mostly in the left or right superior PV. The 3-PVs isolation approach is safe and effective in preventing drug-resistant paroxysmal AF.

Comparison of the efficacy and safety of pulmonary vein isolation using cryoballoon versus radiofrequency ablation for paroxysmal atrial fibrillation： An updated metaanalysis

Background Radiofrequency catheter ablation （RFCA） and cryoballoon ablation （CBA） are the two common ablation technologies used for the treatment of paroxysmal atrial fibrillation （PAF）. However, there is no consensus on which ablation method is the optimal choice. Methods We searched PubMed, EMBASE, Cochrane Library, Web of Knowledge and clinical trials.gov for clinically controlled trials （published up to January 11, 2017）. All included studies included fulfilled our previously defined criteria. The primary clinical outcome was the proportion of participants free from atrial fibrillation at 12-months follow-up. ; The secondary clinical outcomes were as the procedure time, fluoroscopy time, and total complications. Results We identified 573 studies, seven randomized controlled trials （RCTs） and 11 non-RCTs were included in this analysis （n=4982 participants）. Compared with RFCA, CBA had similar proportion of participants free from PAF at 12-months follow-up （70.8% vs. 69%; relative risk [RR] ： 1.01; 95% CI： 0.97 to 1.05）. Additionally, procedure time （149.61 vs. 174.73min; weighted mean difference WMD： 25.55; 95% CI： 44.69 to 6.41） was shorter in the CBA group, but the fluoroscopy time （34.52 vs. 38.59 min; WMD： 2.08; 95% CI： 5.86 to 1.71） did not have any significant difference. Total complication was not significantly different in both groups （RR： 1.22; 95% CI： 0.74 to 2.02 ）. Conclusions CBA is similar to RFCA with respect to clinical efficacy for PAF during the follow-up period of 12 months, and with no increased overall safety risk in the cryoballoon group CBA.

Catheter ablation of atrial fibrillation facilitated by preprocedural three-dimensional transesophageal echocardiography: Long-term outcome

AIM To evaluate the long-term outcome of catheter ablation of atrial fibrillation(AF) facilitated by preprocedural threedimensional(3-D) transesophageal echocardiography.METHODS In 50 patients, 3D transesophageal echocardiography(3D TEE) was performed immediately prior to an ablation procedure(paroxysmal AF: 30 patients, persistent AF: 20 patients). The images were available throughout the ablation procedure. Two different ablation strategies were used. In most of the patients with paroxysmal AF, the cryoablation technique was used(Arctic Front Balloon, Cryo Cath Technologies/Medtronic; group A2). In the other patients, a circumferential pulmonary vein ablation was performed using the CARTO system [Biosense Webster; group A1(paroxysmal AF), group B(persistent AF)]. Success rates and complication rates were analysed at 4-year follow-up.RESULTS A 3D TEE could be performed successfully in all patients prior to the ablation procedure and all four pulmonaryvein ostia could be evaluated in 84% of patients. The image quality was excellent in the majority of patients and several variations of the pulmonary vein anatomy could be visualized precisely(e.g., common pulmonary vein ostia, accessory pulmonary veins, varying diameter of the left atrial appendage and its distance to the left superior pulmonary vein). All ablation procedures could be performed as planned and almost all pulmonary veins could be isolated successfully. At 48-mo followup, 68.0% of all patients were free from an arrhythmia recurrence(group A1: 72.7%, group A2: 73.7%, group B: 60.0%). There were no major complications.CONCLUSION3 D TEE provides an excellent overview over the left atrial anatomy prior to AF ablation procedures and these procedures are associated with a favourable long-term outcome.

Pulmonary vein occlusion and remodeling after electrical isolation treatment for atrial fibrillation: a case report

Pulmonary vein (PV) stenosis or occlusion is a recently describedcomplication of radiofrequency ablation for atrial fibrillation (AF), though favorable results of PVostial ablation have fueled great enthusiasm. The presenting symptoms include dyspnea, cough,hemoptysis, pleural infusion and pulmonary consolidation. We report a case with left PVs occlusionafter ablations, treated with the surgical operation for the PV reconstruction. All the symptomsincluding the left pleural effusion were relieved after the operation. To our knowledge, the case wepresent here is the first surgical operation for PVs occlusion in China's Mainland, which will extendthe understanding of the pulmonary complications and provide an effective strategy for removing thePV occlusion.

Feasibility and safety of cryoballoon ablation for atrial fibrillation inpatients with congenital heart disease

BACKGROUND The prevalence of atrial fibrillation (AF) is on the rise in the aging population with congenital heart disease (CHD). A few case series have described the feasibility and early outcomes associated with radiofrequency catheter ablation of AF centered on electrically isolating pulmonary veins (PV) in patients with CHD. In contrast, cryoballoon ablation has not previously been studied in this patient population despite its theoretical advantages, which include a favorable safety profile and shorter procedural time. AIM To assess the safety and feasibility of cryoballoon ablation for AF in an initial cohort of patients with CHD. METHODS The study population consisted of consecutive patients with CHD and cryoballoon ablation for AF at the Montreal Heart Institute between December 2012 and June 2017. Procedural complications, acute success, and 1-year freedom from recurrent AF after a single procedure with or without antiarrhythmic drugs were assessed. Procedures were performed under conscious sedation. Left atrial access was obtained via a single transseptal puncture or through an existing atrial septal defect (ASD). Cryoballoon occlusion was assessed by distal injection of 50% diluted contrast into the pulmonary vein. At least one 240-second cryothermal application was performed upon obtaining complete pulmonary vein occlusion. Following ablation, patients were routinely followed at outpatient visits at 1, 3, 6, and 12 mo, and then annually. RESULTS Ten patients, median age 57.9 (interquartile range 48.2-61.7) years, 60% female, met inclusion criteria and were followed for 2.8 (interquartile range 1.4-4.5) years.Two had moderately complex CHD (sinus venosus ASD with partial anomalous pulmonary venous return;aortic coarctation with a persistent left superior vena cava), with the remainder having simple defects. AF was paroxysmal in 8 (80.0%) and persistent in 2 (20.0%) patients. The pulmonary vein anatomy was normal in 6 (60.0%) patients. Four had left common PV (n = 3) and/or 3 right PV (n = 2). Electrical pulmonary vein isolation (PVI) was acutely successful in all. One patient had transient phrenic nerve palsy that recovered during the intervention. No major complication occurred. One year after a single ablation procedure, 6 (60%) patients remained free from AF. One patient with recurrent AF had recovered pulmonary vein conduction and underwent a second PVI procedure. A second patient had ablation of an extra-pulmonary vein trigger for AF. CONCLUSION Cryoballoon ablation for AF is feasible and safe in patients with simple and moderate forms of CHD, with an excellent acute success rate and modest 1-year freedom from recurrent AF.

Recurrent atrial tachycardia and atrial fribrillation after circumferential pulmonary vein ablation:What’s the difference?

Background Recurrent atrial tachyarrhythmia （ATa） after circumferential pulmonary vein ablation （CPVA） includes atrial tachycardia （AT） and atrial fribrillation （AF）. However, whether there are some differences in clinical course and mechanisms between the recurrent AT and the recurrent AF remained unclear. This study was conducted to investigate the incidence, mechanism, clinical course of the recurrent AT and AF in patients under CPVA.Methods One hundred and thirty consecutive patients （M/F = 95/35 ） with highly symptomatic ano multiple antiarrhythmic drugs （AADs） refractory paroxysmal （ n = 91 ） or persistent （ n = 39 ） AF were included. The ablation protocol consisted solely of two continuous circular lesions around the ipsilateral pulmonary veins （PV） guided by CARTO system. The endpoint of CPVA is PV isolation. For patients with recurrent ATa within 2 months after the initial procedure, cardioversion with direct current was attempted if the ATa lasted for more than 24 hours. A repeat ablation procedure was performed only for patients with AADs refractory recurrent ATa and at least followed up for 2 months after the initial procedure.Results Within 2 months after the initial procedure, 52 patients （40. 0% ） had experienced episodes of symptomatic recurrent ATa. Among them, 23 patients （44.2%） with recurred AT alone （AT group ）, 14 patients （26.9%） with recurred AF alone （AF group）, and 15 patients （28.8%） with recurred AT and AF （AT plus AF group）. The delayed cure rate （65.2%） in AT group was significant higher than that in AF group （21.4%, P〈0.05） and AF plus AT group （26.7%, P 〈0.05）. A repeat ablation was performed in 21 patients, including 6 patients with recurrent AT alone, 8 patients with recurrent AF alone, and 7 patients with recurrent AF plus AT. The mean number of PV gaps was 1.2 ± 0. 4 in AT group, which was significantly lower than that in AF group （2.6 ± 0. 7, P 〈 0.05） and AF plus AT group （2.0 ± 0.6, P 〈 0.05）. Delayed cure rate and number of PV gaps between AF group and AF plus AT group were comparable （P 〉 0.05 ）. Conclusions Present study indicates that recurrent AT and AF after CPVA have the different clinical course and different electrophysiological findings during repeat procedure as follows： （1）After CPVA, spontaneous resolution of recurrent ATa was mainly found in patients with recurrent AT alone （about two thirds patients）. （2） The type of recurrent ATa after CPVA is associated with the numberof PV gaps.

Catheter ablation of paroxysmal atrial fibrillation in a young patient with a partial anomalous pulmonary venous connection

It has been demonstrated that pulmonary veins （PV）play an important role in the initiation and perpetuation of paroxysmal atrial fibrillation （PAF）.1-5 Therefore, PV isolation has become the cornerstone for catheter ablation in the majority of these AF patients.3-5 In addition, ectopic foci in the non-PVs areas, such as superior vena cava（SVC）,

Impact of different ablation strategies on the delayed cure after trans-catheter ablation for treating patients with atrial fibrillation

Background Delayed cure had been observed in recurrent cases after indexablation of atrial fibrillation ( AF) , however, its mechanism and incidence have not beenelucidated in detail. This study aims to investigate the impact of different ablation strategies onthe incidence of delayed cure and its possible mechanisms after trans-catheter ablation of AF.Methods One hundred and fifty-one consecutive cases with highly symptomatic, drug refractory AF wereincluded in this study [M/F = 109/42, mean age (56. 0 ± 11. 2) (18 -79) years]. Segmentalpulmonary vein ablation (SPVA) was performed in 83 patients with the guidance of circular mappingcatheter (SPVA Group) , circumferential PV linear ablation ( CPVA) was carried out in the rest 68cases under the guidance of 3 dimensional mapping system in conjunction with circular mappingcatheter ( CPVA Group). Delayed cure was defined as that early recurrence of atrial tachyarrhythmias( AF, atrial tachycardia, or atrial flutter) after ablation procedure was no longer observed duringsubsequent follow-up, and stable sinus rhythm was maintained ≥ 2 months. Results Early recurrenceof atrial tachyarrhythmias was detected in 41 cases from SPVA group and 23 cases from CPVA group,and delayed cure occurred in 21. 9% (9/41 ) of the cases from SPVA group and 47. 8% (11/23) of thecases from CPVA group, more delayed cure in later group was observed (P < 0. 05 ) . Meanwhile,patients in SPVA group took a longer time to achieve a delayed cure [ (27. 0 ± 18. 0) days vs (14.0 ±8. 1) days, P <0. 05] , and presented more recurrent episodes [ (3. 50 ± 1. 08) times a week vs(2.42 ± 1. 11) times a week, P <0. 05]. However, recurrent episodes after index ablation weremarkedly decreased in cases with delayed cure from both groups ( P < 0. 05). Conclusions Despite ofan early recurrence of atrial tachyarrhythimas after index ablation of AF, delayed cure occurs in asignificant number of patients undergoing either SPVA or CPVA. However, different ablationstrategies place different impact on the delayed cure, more delayed cure is obtained with CPVAapproach, and the delayed cure occurs earlier with this approach; the average recurrent episodesbefore delayed cure are also less frequently detected in CPVA group compared with those in SPVAgroup.

Left atrial voltage remodeling after pulmonary venous isolation with multipolar radiofrequency ablation

Purpose: Pulmonary vein isolation (PVI) is the accepted primary endpoint for catheter ablation of atrial fibrillation (AF). The aim of this study was to evaluate the level of PVI by PVAC, a multipolar circular catheter utilizing bipolar/unipolar radiofrequency (RF) energy. Methods: Twenty patients with paroxysmal AF underwent PVAC ablation. PVI was validated by voltage reduction and pacing tests. Before and after RF ablation, left atrium (LA) and PV electroanatomic mapping (EAM) were performed by EnSite NavX system. Voltage abatement was considered for potentials 24mm: 9/20 (45%) vs 11/57 (19%),

高功率环肺静脉电隔离常规联合高功率上腔静脉电隔离治疗阵发性心房颤动的临床效果

目的探讨高功率环肺静脉电隔离常规联合高功率上腔静脉电隔离治疗阵发性心房颤动的有效性和安全性。方法选取100例阵发性心房颤动患者,其中50例行单纯高功率环肺静脉电隔离术(对照组);另50例在高功率环肺静脉电隔离术基础上常规行高功率上腔静脉电隔离(试验组),比较两组手术操作时间、1年后心房颤动复发率及并发症发生情况。结果高功率环肺静脉电隔离常规联合高功率上腔静脉电隔离的试验组较对照组手术操作时间延长(P<0.05),但1年后心房颤动复发率降低(P<0.05)。两组各出现1例心包积液,试验组和对照组均未出现窦房结及膈神经损伤。结论高功率环肺静脉电隔离常规联合高功率上腔静脉电隔离治疗阵发性心房颤动是安全的,且与单纯行环肺静脉电隔离相比可有效降低心房颤动术后1年的复发率。

心房颤动环肺静脉隔离联合额外部位消融的疗效评价——一项随机对照试验的Meta分析

目的:探究环肺静脉隔离(CPVI)联合额外部位消融是否比单纯CPVI术后心房颤动(房颤)复发风险低。方法:计算机检索中国知网、万方数据库、维普网、中国生物医学文献数据库、PubMed、Embase、Cochrane图书馆等数据库,筛选出近10年符合标准的随机对照研究,应用Review Manager 5.3软件对文献相关内容进行Meta分析,总结比较单纯CPVI与CPVI联合额外部位消融策略在消融后房颤复发中的差异。结果:共纳入21篇文献,包括21项研究3357例患者,其中1580例行单纯CPVI,1777例行CPVI联合额外部位消融,随访时间均大于1年。Meta分析结果表明,与单纯CPVI相比,CPVI联合额外部位消融未降低房颤复发风险(OR=0.86,95%CI:0.73~1.01,P=0.06)。根据额外消融部位、房颤类型、左心房内径、房颤诊断时间进行亚组分析,发现只在较小的左心房内径亚组中,CPVI联合额外部位消融进一步降低房颤复发风险(OR=0.68,95%CI:0.47~0.98,P=0.04),在其他亚组中未发现上述现象。结论:相比于单纯CPVI,CPVI联合额外部位的消融策略未降低消融后房颤复发风险。

自制穿孔球囊行Marshall静脉无水乙醇消融联合个体化消融策略治疗持续性心房颤动1例

在射频消融术治疗持续性心房颤动(房颤)时常需要在环肺静脉电隔离的基础上增加肺静脉外触发灶的消融,包括线性消融、BOX消融及碎裂电位消融等。二尖瓣峡部是线性消融最重要的组成部分,但传统射频消融很难将二尖瓣峡部进行彻底阻滞。经下腔静脉送入指引导管至冠状静脉窦,Marshall静脉注入无水乙醇消融可实现二尖瓣峡部心外膜和心肌阻滞,再联合二尖瓣峡部心内膜补点消融能显著提升消融效果,但存在Marshall静脉、冠状静脉损伤、手术费用高昂、耗时长等弊端。本文报道1例经自制穿孔球囊行Marshall静脉无水乙醇联合个体化消融策略治疗的持续性房颤患者,出院后随访6个月,无主要不良心血管事件的发生及房颤的复发。

消融指数指导下高功率消融在心房颤动导管消融中的应用

目的:探讨消融指数(ablation index,AI)指导下高功率消融在心房颤动导管消融中的应用价值。方法:入选2020年4月至2023年7月,在皖南医学院附属宣城医院住院的阵发性及持续性心房颤动患者158例。根据入组时间先后顺序分为两组,常规组(71例)消融功率设为30~35W,高功率组(87例)设为40W,高功率组以AI值为参考进行导管射频消融,以达到肺静脉前庭电隔离为消融目标,必要时加辅助线消融。对比两组的手术时间、单点消融时间、肺静脉隔离(pulmonary vein isolation,PVI)时间、X线曝光时间、肺静脉单圈隔离率、肺静脉即时隔离率、并发症发生率、心房颤动复发情况。结果:与常规组相比,高功率组的手术时间、单点消融时间、PVI时间和X线曝光时间均明显更短(P<0.05),液体灌注量明显更少(P<0.05)。肺静脉即时隔离率均为100.00%,但高功率组的PVI单圈隔离率显著高于常规组(P<0.05)。高功率组的消融并发症总发生率与常规组无统计学差异。高功率组心房颤动复发率为10.3%,显著低于常规组的23.9%(P<0.05)。结论:以AI值为参考的高功率射频消融治疗心房颤动的消融效率高,同时能提高肺静脉单圈隔离率,降低心房颤动复发率,疗效好,并发症少,该消融策略安全可行。

Marshall静脉无水乙醇消融治疗持续性房颤的临床疗效分析

目的:探索Marshall静脉无水乙醇消融联合导管射频消融术治疗持续性房颤的有效性和安全性。方法:选取2021年8月—2022年6月就诊于荆州市中心医院的120例持续性房颤患者,按照是否行Marshall静脉无水乙醇消融术分为两组,对照组行导管射频消融术(n=60),试验组行Marshall静脉无水乙醇消融联合导管射频消融术(n=60)。比较两组患者二尖瓣峡部阻滞成功率、术后房颤复发情况及手术并发症。结果:试验组患者二尖瓣峡部阻滞成功率显著高于对照组(98.33%vs 68.33%,P<0.001),术后12个月时,试验组的房颤复发率显著低于对照组(15.00%vs 36.67%,P<0.05)。两组患者术后均未出现严重并发症。结论:相较于单纯导管射频消融术,Marshall静脉无水乙醇消融联合导管射频消融治疗持续性房颤疗效更优且远期复发率更低,值得临床推广应用。